Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial.

Senders A, Hanes D, Bourdette D, Carson K, Marshall LM, Shinto L.

Mult Scler. 2018 Jul 1:1352458518786650. doi: 10.1177/1352458518786650. [Epub ahead of print]

PMID:
29985095
2.

Using the Anterior Visual System to Assess Neuroprotection and Remyelination in Multiple Sclerosis Trials.

Silbermann E, Wooliscroft L, Bourdette D.

Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):49. doi: 10.1007/s11910-018-0858-y. Review.

PMID:
29923130
3.

Hypothalamic-Pituitary-Thyroid Axis Perturbations in Male Mice by CNS-Penetrating Thyromimetics.

Ferrara SJ, Bourdette D, Scanlan TS.

Endocrinology. 2018 Jul 1;159(7):2733-2740. doi: 10.1210/en.2018-00065.

PMID:
29846550
4.

A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Long-term (12-month) follow-up at one site.

Hugos CL, Cameron MH, Chen Z, Chen Y, Bourdette D.

Mult Scler. 2018 May 1:1352458518775920. doi: 10.1177/1352458518775920. [Epub ahead of print]

PMID:
29761722
5.

Uses of H.P. Acthar Gel in the Clinical Setting-Reply.

Hartung DM, Bourdette DN, Cohen DM.

JAMA Intern Med. 2018 Apr 1;178(4):583-584. doi: 10.1001/jamainternmed.2017.8545. No abstract available.

PMID:
29610884
6.

Meals, Mindfulness, & Moving Forward: A feasibility study to a multi-modal lifestyle approach in early psychosis.

Usher C, Thompson A, Griebeler M, Senders A, Seibel C, Ly R, Murchison C, Hagen K, Afong KA, Bourdette D, Ross R, Borgatti A, Shinto L.

Early Interv Psychiatry. 2018 Mar 7. doi: 10.1111/eip.12546. [Epub ahead of print]

PMID:
29512356
7.

Elephant in the room.

Hartung DM, Johnston K, Cohen DM, Nguyen T, Deodhar AA, Bourdette DN.

Ann Rheum Dis. 2018 Jan 23. pii: annrheumdis-2018-213008. doi: 10.1136/annrheumdis-2018-213008. [Epub ahead of print] No abstract available.

PMID:
29363509
8.

Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis.

George JD, Kim E, Spain R, Bourdette D, Salinthone S.

J Neuroimmunol. 2018 Feb 15;315:24-27. doi: 10.1016/j.jneuroim.2017.12.009. Epub 2017 Dec 19.

PMID:
29306401
9.

A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Short- and medium-term benefits.

Hugos CL, Chen Z, Chen Y, Turner AP, Haselkorn J, Chiara T, McCoy S, Bever CT Jr, Cameron MH, Bourdette D; VA MS Fatigue Study Group.

Mult Scler. 2017 Dec 1:1352458517745723. doi: 10.1177/1352458517745723. [Epub ahead of print]

PMID:
29226778
10.

Diet in multiple sclerosis: Science takes a seat at the table.

Sumowski JF, McDonnell GV, Bourdette D.

Neurology. 2018 Jan 2;90(1):14-15. doi: 10.1212/WNL.0000000000004775. Epub 2017 Dec 6. No abstract available.

PMID:
29212826
11.

Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects.

Fiedler SE, Yadav V, Kerns AR, Tsang C, Markwardt S, Kim E, Spain R, Bourdette D, Salinthone S.

Mol Neurobiol. 2018 Jul;55(7):6037-6049. doi: 10.1007/s12035-017-0813-y. Epub 2017 Nov 15.

PMID:
29143287
12.

Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.

Winges KM, Murchison CF, Bourdette DN, Spain RI.

Mult Scler. 2017 Nov 1:1352458517739136. doi: 10.1177/1352458517739136. [Epub ahead of print]

PMID:
29111873
13.

Analysis of IL-6, IL-1β and TNF-α production in monocytes isolated from multiple sclerosis patients treated with disease modifying drugs.

Fiedler SE, George JD, Love HN, Kim E, Spain R, Bourdette D, Salinthone S.

J Syst Integr Neurosci. 2017 May;3(3). doi: 10.15761/JSIN.1000166. Epub 2017 Jun 17.

14.

MIF and D-DT are potential disease severity modifiers in male MS subjects.

Benedek G, Meza-Romero R, Jordan K, Zhang Y, Nguyen H, Kent G, Li J, Siu E, Frazer J, Piecychna M, Du X, Sreih A, Leng L, Wiedrick J, Caillier SJ, Offner H, Oksenberg JR, Yadav V, Bourdette D, Bucala R, Vandenbark AA.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8421-E8429. doi: 10.1073/pnas.1712288114. Epub 2017 Sep 18.

15.

Trends and Characteristics of US Medicare Spending on Repository Corticotropin.

Hartung DM, Johnston K, Van Leuven S, Deodhar A, Cohen DM, Bourdette DN.

JAMA Intern Med. 2017 Nov 1;177(11):1680-1682. doi: 10.1001/jamainternmed.2017.3631. No abstract available.

16.

Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?

Wiendl H, Bourdette D, Ciccarelli O.

Neurology. 2017 Sep 12;89(11):1098-1100. doi: 10.1212/WNL.0000000000004381. Epub 2017 Aug 23. No abstract available.

PMID:
28835406
17.

Optical coherence tomography angiography enhances the detection of optic nerve damage in multiple sclerosis.

Spain RI, Liu L, Zhang X, Jia Y, Tan O, Bourdette D, Huang D.

Br J Ophthalmol. 2018 Apr;102(4):520-524. doi: 10.1136/bjophthalmol-2017-310477. Epub 2017 Aug 16.

PMID:
28814415
18.

Author response: Neurologists and the economics of MS treatment: Lighting candles, not cursing the darkness.

Bourdette DN.

Neurology. 2017 Aug 1;89(5):520-521. doi: 10.1212/WNL.0000000000004194. No abstract available.

PMID:
28760917
19.

Targeting Fatty-Acid Amide Hydrolase with Prodrugs for CNS-Selective Therapy.

Meinig JM, Ferrara SJ, Banerji T, Banerji T, Sanford-Crane HS, Bourdette D, Scanlan TS.

ACS Chem Neurosci. 2017 Nov 15;8(11):2468-2476. doi: 10.1021/acschemneuro.7b00239. Epub 2017 Aug 18.

PMID:
28756656
20.

Lipoic Acid Pharmacokinetics at Baseline and 1 year in Secondary Progressive MS.

Bittner F, Murchison C, Koop D, Bourdette D, Spain R.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 28;4(5):e380. doi: 10.1212/NXI.0000000000000380. eCollection 2017 Sep. No abstract available.

21.

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.

Spain R, Powers K, Murchison C, Heriza E, Winges K, Yadav V, Cameron M, Kim E, Horak F, Simon J, Bourdette D.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 28;4(5):e374. doi: 10.1212/NXI.0000000000000374. eCollection 2017 Sep.

22.

A group-delivered self-management program reduces spasticity in people with multiple sclerosis: A randomized, controlled pilot trial.

Hugos CL, Bourdette D, Chen Y, Chen Z, Cameron M.

Mult Scler J Exp Transl Clin. 2017 Mar 23;3(1):2055217317699993. doi: 10.1177/2055217317699993. eCollection 2017 Jan-Mar.

23.

MS and bone marrow transplant: Not for most patients.

Frederick MC, Bourdette D.

Neurology. 2017 May 30;88(22):e219-e220. doi: 10.1212/WNL.0000000000004001. No abstract available.

PMID:
28554907
24.

Sex-dependent treatment of chronic EAE with partial MHC class II constructs.

Benedek G, Chaudhary P, Meza-Romero R, Calkins E, Kent G, Offner H, Bourdette D, Vandenbark AA.

J Neuroinflammation. 2017 May 6;14(1):100. doi: 10.1186/s12974-017-0873-y.

25.

Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration.

Ferrara SJ, Meinig JM, Placzek AT, Banerji T, McTigue P, Hartley MD, Sanford-Crane HS, Banerji T, Bourdette D, Scanlan TS.

Bioorg Med Chem. 2017 May 15;25(10):2743-2753. doi: 10.1016/j.bmc.2017.03.047. Epub 2017 Mar 23.

26.

Sleep and its associations with perceived and objective cognitive impairment in individuals with multiple sclerosis.

Hughes AJ, Parmenter BA, Haselkorn JK, Lovera JF, Bourdette D, Boudreau E, Cameron MH, Turner AP.

J Sleep Res. 2017 Aug;26(4):428-435. doi: 10.1111/jsr.12490. Epub 2017 Jan 17.

27.

Early Fever As a Predictor of Paroxysmal Sympathetic Hyperactivity in Traumatic Brain Injury.

Hinson HE, Schreiber MA, Laurie AL, Baguley IJ, Bourdette D, Ling GSF.

J Head Trauma Rehabil. 2017 Sep/Oct;32(5):E50-E54. doi: 10.1097/HTR.0000000000000271.

28.

Neurologists and the economics of MS treatment: Lighting candles, not cursing the darkness.

Bourdette D, Whitham R.

Neurology. 2016 Oct 11;87(15):1532-1533. Epub 2016 Sep 2. No abstract available.

PMID:
27590289
29.

Rituximab for treating multiple sclerosis: Off-label but on target.

Bourdette D.

Neurology. 2016 Nov 15;87(20):2070-2071. Epub 2016 Oct 19. No abstract available.

PMID:
27760871
30.

Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.

Yadav V, Marracci G, Kim E, Spain R, Cameron M, Overs S, Riddehough A, Li DK, McDougall J, Lovera J, Murchison C, Bourdette D.

Mult Scler Relat Disord. 2016 Sep;9:80-90. doi: 10.1016/j.msard.2016.07.001. Epub 2016 Jul 6.

31.

The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.

Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG.

Neurology. 2016 Sep 27;87(13):1393-9. doi: 10.1212/WNL.0000000000003152. Epub 2016 Aug 31.

32.

US health insurance is an obstacle to disease-modifying treatments in MS.

Bourdette D, Patti F.

Neurology. 2016 Jul 26;87(4):346-7. doi: 10.1212/WNL.0000000000002904. Epub 2016 Jun 29. No abstract available.

PMID:
27358336
33.

Dimethyl fumarate activates the prostaglandin EP2 receptor and stimulates cAMP signaling in human peripheral blood mononuclear cells.

Fiedler SE, Kerns AR, Tsang C, Tsang V, Bourdette D, Salinthone S.

Biochem Biophys Res Commun. 2016 Jun 17;475(1):19-24. doi: 10.1016/j.bbrc.2016.05.021. Epub 2016 May 5.

PMID:
27157139
34.
35.

Spatio-Temporal Patterns of Demyelination and Remyelination in the Cuprizone Mouse Model.

Tagge I, O'Connor A, Chaudhary P, Pollaro J, Berlow Y, Chalupsky M, Bourdette D, Woltjer R, Johnson M, Rooney W.

PLoS One. 2016 Apr 7;11(4):e0152480. doi: 10.1371/journal.pone.0152480. eCollection 2016.

36.

Author response.

Hartung DM, Bourdette DN, Ahmed S, Whitham RH.

Neurology. 2015 Nov 10;85(19):1728. No abstract available.

PMID:
26866143
37.

Author response.

Hartung DM, Bourdette DN, Whitham RH.

Neurology. 2015 Nov 10;85(19):1727. No abstract available.

PMID:
26866141
38.

Author response.

Hartung DM, Bourdette DN, Ahmed S, Whitham RH.

Neurology. 2015 Nov 10;85(19):1728. No abstract available.

PMID:
26866072
39.

Author response.

Hartung DM, Bourdette DN, Whitham RH.

Neurology. 2015 Nov 10;85(19):1727. No abstract available.

PMID:
26866070
40.

Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis.

Blair TC, Manoharan M, Rawlings-Rhea SD, Tagge I, Kohama SG, Hollister-Smith J, Ferguson B, Woltjer RL, Frederick MC, Pollaro J, Rooney WD, Sherman LS, Bourdette DN, Wong SW.

J Neuroimmunol. 2016 Feb 15;291:1-10. doi: 10.1016/j.jneuroim.2015.11.026. Epub 2015 Dec 2.

41.

Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study.

Shinto L, Marracci G, Mohr DC, Bumgarner L, Murchison C, Senders A, Bourdette D.

PLoS One. 2016 Jan 22;11(1):e0147195. doi: 10.1371/journal.pone.0147195. eCollection 2016.

42.

Lipoic acid reduces inflammation in a mouse focal cortical experimental autoimmune encephalomyelitis model.

Chaudhary P, Marracci G, Galipeau D, Pocius E, Morris B, Bourdette D.

J Neuroimmunol. 2015 Dec 15;289:68-74. doi: 10.1016/j.jneuroim.2015.10.011. Epub 2015 Nov 11.

43.

Medications Are Associated with Falls in People with Multiple Sclerosis: A Prospective Cohort Study.

Cameron MH, Karstens L, Hoang P, Bourdette D, Lord S.

Int J MS Care. 2015 Sep-Oct;17(5):207-14. doi: 10.7224/1537-2073.2014-076.

44.

Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis.

Bourdette D, Hartung D.

JAMA Neurol. 2015 Dec;72(12):1411-3. doi: 10.1001/jamaneurol.2015.2605. No abstract available. Erratum in: JAMA Neurol. 2015 Dec;72(12):1537.

PMID:
26457848
45.

Fear of Falling Is Associated with Recurrent Falls in People with Multiple Sclerosis: A Longitudinal Cohort Study.

Mazumder R, Lambert WE, Nguyen T, Bourdette DN, Cameron MH.

Int J MS Care. 2015 Jul-Aug;17(4):164-70. doi: 10.7224/1537-2073.2014-042.

46.

Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.

Lovera J, Ramos A, Devier D, Garrison V, Kovner B, Reza T, Koop D, Rooney W, Foundas A, Bourdette D.

J Neurol Sci. 2015 Nov 15;358(1-2):46-52. doi: 10.1016/j.jns.2015.08.006. Epub 2015 Aug 7.

47.

Cognitive Impairment and Community Integration Outcomes in Individuals Living With Multiple Sclerosis.

Hughes AJ, Hartoonian N, Parmenter B, Haselkorn JK, Lovera JF, Bourdette D, Turner AP.

Arch Phys Med Rehabil. 2015 Nov;96(11):1973-9. doi: 10.1016/j.apmr.2015.07.003. Epub 2015 Jul 17.

PMID:
26189203
48.

Natalizumab to fingolimod: Questions answered, unanswered, and unasked.

Stüve O, Bourdette D.

Neurology. 2015 Jul 7;85(1):14-5. doi: 10.1212/WNL.0000000000001722. Epub 2015 May 29. No abstract available.

PMID:
26024898
49.

Mapping human brain capillary water lifetime: high-resolution metabolic neuroimaging.

Rooney WD, Li X, Sammi MK, Bourdette DN, Neuwelt EA, Springer CS Jr.

NMR Biomed. 2015 Jun;28(6):607-23. doi: 10.1002/nbm.3294. Epub 2015 Apr 27.

50.

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

Hartung DM, Bourdette DN, Ahmed SM, Whitham RH.

Neurology. 2015 May 26;84(21):2185-92. doi: 10.1212/WNL.0000000000001608. Epub 2015 Apr 24. Erratum in: Neurology. 2015 Nov 10;85(19):1728.

Supplemental Content

Loading ...
Support Center